Versantis develops a new generation of effective medicines and reliable diagnostics to revolutionize the care of patients with liver disease. Its lead candidate, VS-01, has the potential to fill the medical gap between preventive drugs and liver transplantations, and received Orphan Drug Designations from both the FDA and EMA. With a pipeline embracing a broad range of indications, Versantis aims to answer the unmet medical need of millions of people worldwide.
Versantis raised a CHF 4.4M series A in 2017 and has been rewarded with the most prestigious scientific and entrepreneurial prizes.
Keep an eye on this company by adding it to your watchlist.